These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25048494)

  • 1. Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation.
    Oh CK; Huh KH; Lee JS; Cho HR; Kim YS
    Yonsei Med J; 2014 Sep; 55(5):1341-7. PubMed ID: 25048494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
    Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
    Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature.
    Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A
    Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: A prospective cohort study.
    Oh CK; Bang JB; Kim SJ; Huh KH; Kim SJ; Jeon JS; Han SY; Cho HR; Kwon YJ; Lee SH; Kim YS
    Asian J Surg; 2020 Jun; 43(6):660-667. PubMed ID: 31353239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.
    Bunnapradist S; Ciechanowski K; West-Thielke P; Mulgaonkar S; Rostaing L; Vasudev B; Budde K;
    Am J Transplant; 2013 Mar; 13(3):760-9. PubMed ID: 23279614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
    Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
    Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients.
    Guirado L; Cantarell C; Franco A; Huertas EG; Fructuoso AS; Fernández A; Gentil MA; Rodríguez A; Paul J; Torregrossa JV; Rodríguez A; Alonso A; Hernández D; Burgos D; Jiménez C; Jimeno L; Lauzurica R; Mazuecos A; Osuna A; Plumed JS; Ruiz JC; Zárraga S;
    Am J Transplant; 2011 Sep; 11(9):1965-71. PubMed ID: 21668633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study.
    Lee EC; Kim SH; Park SJ
    Ann Transplant; 2018 Oct; 23():713-720. PubMed ID: 30310047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot Study Comparing the Efficacy, Safety, Convertibility, and Tacrolimus Trough Levels of Twice-Daily Tacrolimus (Prograf) to Once-Daily Tacrolimus (Advagraf) Among Standard-Risk Kidney Transplant Patients at the National Kidney and Transplant Institute.
    Danguilan RA; Lamban A; Pamugas GEP
    Transplant Proc; 2019 Oct; 51(8):2615-2619. PubMed ID: 31563241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization.
    Ho B; Bhagat H; Schwartz JJ; Atiemo K; Daud A; Kang R; Montag SE; Zhao L; Lee E; Skaro AI; Ladner DP
    Adv Ther; 2019 Jun; 36(6):1465-1479. PubMed ID: 30941724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
    Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
    Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan.
    Takahashi K; Abe R; Usuki S; So M
    Transplant Proc; 2014; 46(2):406-10. PubMed ID: 24655975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients.
    Bäckman L; Persson CA
    Ann Transplant; 2014 Mar; 19():138-44. PubMed ID: 24637379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
    Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
    Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.